These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 33309483)

  • 21. Tandem truncated rotavirus VP8* subunit protein with T cell epitope as non-replicating parenteral vaccine is highly immunogenic.
    Wen X; Cao D; Jones RW; Hoshino Y; Yuan L
    Hum Vaccin Immunother; 2015; 11(10):2483-9. PubMed ID: 26091081
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of serum antibody responses against the rotavirus nonstructural protein NSP4 in children after rhesus rotavirus tetravalent vaccination or natural infection.
    Vizzi E; Calviño E; González R; Pérez-Schael I; Ciarlet M; Kang G; Estes MK; Liprandi F; Ludert JE
    Clin Diagn Lab Immunol; 2005 Oct; 12(10):1157-63. PubMed ID: 16210477
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Yeast expression of the VP8* fragment of the rotavirus spike protein and its use as immunogen in mice.
    Andrés I; Rodríguez-Díaz J; Buesa J; Zueco J
    Biotechnol Bioeng; 2006 Jan; 93(1):89-98. PubMed ID: 16193515
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design and testing of a highly conserved human rotavirus VP8* immunogenic peptide with potential for vaccine development.
    Mohanty E; Dehury B; Satapathy AK; Dwibedi B
    J Biotechnol; 2018 Sep; 281():48-60. PubMed ID: 29886031
    [TBL] [Abstract][Full Text] [Related]  

  • 25. VP8* antigen produced in tobacco transplastomic plants confers protection against bovine rotavirus infection in a suckling mouse model.
    Lentz EM; Mozgovoj MV; Bellido D; Dus Santos MJ; Wigdorovitz A; Bravo-Almonacid FF
    J Biotechnol; 2011 Nov; 156(2):100-7. PubMed ID: 21893114
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and immunogenicity of a parenteral P2-VP8-P[8] subunit rotavirus vaccine in toddlers and infants in South Africa: a randomised, double-blind, placebo-controlled trial.
    Groome MJ; Koen A; Fix A; Page N; Jose L; Madhi SA; McNeal M; Dally L; Cho I; Power M; Flores J; Cryz S
    Lancet Infect Dis; 2017 Aug; 17(8):843-853. PubMed ID: 28483414
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Co-administration of rotavirus nanospheres VP6 and NSP4 proteins enhanced the anti-NSP4 humoral responses in immunized mice.
    Afchangi A; Jalilvand S; Arashkia A; Latifi T; Farahmand M; Abolghasem Shirazi MM; Mousavi Nasab SD; Marashi SM; Roohvand F; Shoja Z
    Microb Pathog; 2022 Feb; 163():105405. PubMed ID: 35045328
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dual Recognition of Sialic Acid and αGal Epitopes by the VP8* Domains of the Bovine Rotavirus G6P[5] WC3 and of Its Mono-reassortant G4P[5] RotaTeq Vaccine Strains.
    Alfajaro MM; Kim JY; Barbé L; Cho EH; Park JG; Soliman M; Baek YB; Kang MI; Kim SH; Kim GJ; Park SI; Pendu JL; Cho KO
    J Virol; 2019 Sep; 93(18):. PubMed ID: 31243129
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oral immunization of mice with Lactococcus lactis expressing the rotavirus VP8* protein.
    Rodríguez-Díaz J; Montava R; Viana R; Buesa J; Pérez-Martínez G; Monedero V
    Biotechnol Lett; 2011 Jun; 33(6):1169-75. PubMed ID: 21302132
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic diversity of G1P[8] rotavirus VP7 and VP8* antigens in Finland over a 20-year period: No evidence for selection pressure by universal mass vaccination with RotaTeq® vaccine.
    Hemming M; Vesikari T
    Infect Genet Evol; 2013 Oct; 19():51-8. PubMed ID: 23831933
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization and immunogenicity of a novel chimeric hepatitis B core-virus like particles (cVLPs) carrying rotavirus VP8*protein in mice model.
    Latifi T; Jalilvand S; Golsaz-Shirazi F; Arashkia A; Kachooei A; Afchangi A; Zafarian S; Roohvand F; Shoja Z
    Virology; 2023 Nov; 588():109903. PubMed ID: 37832344
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recombinant Subunit Rotavirus Trivalent Vaccine Candidate: Physicochemical Comparisons and Stability Evaluations of Three Protein Antigens.
    Agarwal S; Hickey JM; Sahni N; Toth RT; Robertson GA; Sitrin R; Cryz S; Joshi SB; Volkin DB
    J Pharm Sci; 2020 Jan; 109(1):380-393. PubMed ID: 31400347
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of the efficacy of rotavirus VLP vaccines to a live homologous rotavirus vaccine in a pig model of rotavirus disease.
    El-Attar L; Oliver SL; Mackie A; Charpilienne A; Poncet D; Cohen J; Bridger JC
    Vaccine; 2009 May; 27(24):3201-8. PubMed ID: 19446192
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Brucella spp. lumazine synthase as a bovine rotavirus antigen delivery system.
    Bellido D; Craig PO; Mozgovoj MV; Gonzalez DD; Wigdorovitz A; Goldbaum FA; Dus Santos MJ
    Vaccine; 2009 Jan; 27(1):136-45. PubMed ID: 18973781
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Induction of mucosal immune responses and protection against enteric viruses: rotavirus infection of gnotobiotic pigs as a model.
    Yuan L; Saif LJ
    Vet Immunol Immunopathol; 2002 Sep; 87(3-4):147-60. PubMed ID: 12072229
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination of three virus-derived nanoparticles as a vaccine against enteric pathogens; enterovirus, norovirus and rotavirus.
    Heinimäki S; Hankaniemi MM; Sioofy-Khojine AB; Laitinen OH; Hyöty H; Hytönen VP; Vesikari T; Blazevic V
    Vaccine; 2019 Dec; 37(51):7509-7518. PubMed ID: 31585726
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inclusion of a universal tetanus toxoid CD4(+) T cell epitope P2 significantly enhanced the immunogenicity of recombinant rotavirus ΔVP8* subunit parenteral vaccines.
    Wen X; Wen K; Cao D; Li G; Jones RW; Li J; Szu S; Hoshino Y; Yuan L
    Vaccine; 2014 Jul; 32(35):4420-4427. PubMed ID: 24962749
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunological response to recombinant VP8* subunit protein of bovine roravirus in pregnant cattle.
    Lee J; Babiuk LA; Harland R; Gibbons E; Elazhary Y; Yoo D
    J Gen Virol; 1995 Oct; 76 ( Pt 10)():2477-83. PubMed ID: 7595351
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glycan Binding Specificity and Mechanism of Human and Porcine P[6]/P[19] Rotavirus VP8*s.
    Sun X; Li D; Qi J; Chai W; Wang L; Wang L; Peng R; Wang H; Zhang Q; Pang L; Kong X; Wang H; Jin M; Gao GF; Duan Z
    J Virol; 2018 Jul; 92(14):. PubMed ID: 29720519
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Passive protection to bovine rotavirus (BRV) infection induced by a BRV VP8* produced in plants using a TMV-based vector.
    Pérez Filgueira DM; Mozgovoj M; Wigdorovitz A; Dus Santos MJ; Parreño V; Trono K; Fernandez FM; Carrillo C; Babiuk LA; Morris TJ; Borca MV
    Arch Virol; 2004 Dec; 149(12):2337-48. PubMed ID: 15338319
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.